Literature DB >> 4087291

Riboflavin as a tracer of medication compliance.

P M Dubbert, A King, S R Rapp, D Brief, J E Martin, M Lake.   

Abstract

Three experiments were conducted to evaluate the accuracy of urine ultraviolet fluorescent tests for riboflavin, which has been used as a tracer for medication compliance in several clinical drug trials. Observer accuracy in discriminating riboflavin-positive or negative urine samples was found to vary with the method of observation, dose of riboflavin, observer experience, and time postingestion. The results showed that, while the 5-mg dose used in previous clinical trials was too small to permit reliable assessment of compliance, larger doses of riboflavin could produce nearly 100% accuracy for minimally trained observers who used a matching-to-sample observation procedure. The findings are discussed in terms of the potential clinical and research applications of this type of simple but reliable compliance assessment procedure.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087291     DOI: 10.1007/BF00870315

Source DB:  PubMed          Journal:  J Behav Med        ISSN: 0160-7715


  10 in total

1.  Clinical usefulness of riboflavin-tagged isoniazid for self-medication in tuberculous patients.

Authors:  K W DEUSCHLE; C JORDAHL; G L HOBBY
Journal:  Am Rev Respir Dis       Date:  1960-07

2.  Contracting with patients to improve compliance.

Authors:  S B Steckel; M A Swain
Journal:  Hospitals       Date:  1977-12-01

3.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.

Authors: 
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

4.  Multiclinic controlled trial of bethanidine and guanethidine in severe hypertension.

Authors:  E A Ramirez; L Elson; A S Gear; J R Oster; F N Talmers; J R Thomas
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

5.  Effect of compliance for chronic asthmatic children.

Authors:  P A Cluss; L H Epstein; S A Galvis; P Fireman; G Friday
Journal:  J Consult Clin Psychol       Date:  1984-10

6.  A behavioral medicine perspective on adherence to long-term medical regimens.

Authors:  L H Epstein; P A Cluss
Journal:  J Consult Clin Psychol       Date:  1982-12

7.  Behavioral control of medicine compliance.

Authors:  L H Epstein; B J Masek
Journal:  J Appl Behav Anal       Date:  1978

8.  Increasing patient compliance with prescriptions.

Authors:  C L Peck; N J King
Journal:  JAMA       Date:  1982-12-03       Impact factor: 56.272

9.  Propranolol in the treatment of essential hypertension.

Authors: 
Journal:  JAMA       Date:  1977-05-23       Impact factor: 56.272

10.  Can dropout and other noncompliance be minimized in a clinical trial? Report from the Veterans Administrative National Heart, Lung and Blood Institute cooperative study on antihypertensive therapy: mild hypertension.

Authors:  A I Goldman; R Holcomb; H M Perry; H W Schnaper; A E Fitz; E D Frohlich
Journal:  Control Clin Trials       Date:  1982-06
  10 in total
  6 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  How useful is riboflavin as a tracer of medication compliance?

Authors:  I E Babiker; P R Cooke; M G Gillett
Journal:  J Behav Med       Date:  1989-02

3.  Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement.

Authors:  Abigail J Herron; John J Mariani; Martina Pavlicova; Christina M Parrinello; Krysten W Bold; Frances R Levin; Edward V Nunes; Maria A Sullivan; Wilfred N Raby; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2012-08-22       Impact factor: 4.492

4.  Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.

Authors:  Sarah W Book; Suzanne E Thomas; Patrick K Randall; Carrie L Randall
Journal:  J Anxiety Disord       Date:  2007-03-12

5.  The Nigerian antihypertensive adherence trial: a community-based randomized trial.

Authors:  Adebowale Adeyemo; Bamidele O Tayo; Amy Luke; Olugbenga Ogedegbe; Ramon Durazo-Arvizu; Richard S Cooper
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

6.  Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial.

Authors:  Cenk Tek; Sinan Guloksuz; Vinod H Srihari; Erin L Reutenauer
Journal:  BMC Psychiatry       Date:  2013-06-27       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.